Wolfgang Miesbach/LinkedIn
May 13, 2026, 15:10
Wolfgang Miesbach: Rethinking Bleeding Risk in Anticoagulation
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn:
“Rethinking Bleeding Risk in Anticoagulation.
At the EHA‑SWG Scientific Meeting on Bleeding and Platelet Disorders, Mariantonietta Tripodo delivered a fantastic talk on bleeding risk in patients receiving antithrombotic therapy – from AF and VTE to prosthetic valves, LV thrombus and acute coronary syndromes:
- Antithrombotic therapy is used across many indications, so managing bleeding risk is a daily challenge in routine practice.
- Major bleeding (incl. ICH) remains a major limitation of VKAs and DOACs, and ‘fear‑driven’ underdosing in real life is still common.
- High‑risk patients (age, renal impairment, prior bleeding) live within a narrow therapeutic window, making individualized decisions essential.
- Targeting FXI could help decouple thrombosis from hemostasis, with early data suggesting relevant bleeding reduction while preserving efficacy.”
Other posts featuring Wolfgang Miesbach on Hemostasis Today.
-
Jun 27, 2026, 18:19Nabil Tabish: The Paradox of Zero – Investigating Extreme VWF Discordance
-
Jun 27, 2026, 18:19Francesco Favruzzo: Can Mechanical Thrombectomy Be Safely Used in Cervical Artery Dissection?
-
Jun 27, 2026, 18:18Vera Ghali: 2026 ASH–ISTH Recommendations on Pediatric VTE Prevention
-
Jun 27, 2026, 18:17Michiel Coppens: A Hemostasis Laboratory – One of the Cornerstones of Our Hemophilia Mission
-
Jun 27, 2026, 18:16Sthanu Subramanian: Dabigatran and Mechanical Heart Valves
-
Jun 27, 2026, 15:50Muhammet Özbilen: The Skin as an Emerging Regulator of Iron Homeostasis
-
Jun 27, 2026, 15:07Anteneh Berhane: Supporting Healthier Pregnancies Through Early Nutrition
-
Jun 27, 2026, 14:35Mobina Nakhaei: Why Alloantibodies Develop Despite ABO/Rh Matching in Thalassemia
-
Jun 27, 2026, 14:01Abdul Mannan: DOACs in Cancer-Associated VTE – When to Avoid Them, And When LMWH Wins